About the Company
We do not have any company description for Silexion Therapeutics Corp at the moment.
Exchange
Nasdaq
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest News on Silexion Therapeutics Corp
Silexion Therapeutics Corp. Reports 2024 Financial Results and ... - Nasdaq
Silexion Therapeutics Corp. announced its financial results for the fourth quarter and full year ended December 31, 2024, highlighting a transformative year marked by its Nasdaq listing and ...
Silexion Therapeutics Executes Reverse Stock Split
Silexion Therapeutics ( ($SLXN) ) has shared an announcement. On July 28, 2025, Silexion Therapeutics Corp implemented a 1-for-15 reverse share ...
Silexion Therapeutics Corp. Announces Expanded Development ... - Nasdaq
Silexion Therapeutics Corp., a biotechnology company focused on RNA interference therapies for KRAS-driven cancers, announced the completion of an expanded development plan for its siRNA candidate ...
Silexion Therapeutics Unveils Innovative Expanded Development Plan for ...
Grand Cayman, Cayman Islands, March 28, 2025 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. (NASDAQ: SLXN) (“Silexion” or the “Company”), a clinical-stage biotechnology company pioneering ...
Silexion Therapeutics Corp: Silexion Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update
Silexion Therapeutics Corp. (NASDAQ: SLXN) ("Silexion" or the "Company"), a clinical-stage biotechnology company developing RNA interference ...
Silexion Therapeutics Increases Authorized Share Capital
Silexion Therapeutics ( ($SLXN) ) has provided an announcement. At the extraordinary general meeting of Silexion Therapeutics Corp, originally ...
Silexion Therapeutics Announces New Preclinical Data Showing Up to 97% ...
Grand Cayman, July 31, 2025 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. (NASDAQ: SLXN) ("Silexion" or the "Company"), a clinical-stage biotechnology company pioneering RNA interference (RNAi ...
Silexion Therapeutics' Preclinical Cancer Candidate Shows Tumor ...
Silexion is actively exploring an expanded development plan for SIL204 using the systemic administration approach. Price Action: SLXN stock is up 25.23% at $1.39 at publication Wednesday. Read Next: ...
Silexion Therapeutics Corp (SLXN)’s RNAi Therapy Blocks 90% of ...
Silexion Therapeutics Corp (NASDAQ:SLXN) has announced breakthrough preclinical results for its next-generation RNA interference (RNAi) therapy, SIL204, showing potent anti-tumor effects across ...
Similar Companies
Loading the latest forecasts...